These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Outcome analysis of cervical adenosquamous carcinoma compared with adenocarcinoma.
    Author: Chen JL, Cheng JC, Kuo SH, Chen CA, Lin MC, Huang CY.
    Journal: Acta Obstet Gynecol Scand; 2012 Oct; 91(10):1158-66. PubMed ID: 22497449.
    Abstract:
    OBJECTIVE: To compare survival between patients with cervical adenocarcinoma (AC) and adenosquamous carcinoma (ASC). DESIGN: Retrospective study. SETTING: National Taiwan University Hospital, Taipei, Taiwan. POPULATION: All patients with cervical AC or ASC who received definitive treatment from January 1995 to December 2009. METHODS: Medical and histopathological record review. MAIN OUTCOME MEASURES: Overall and recurrence-free survival. RESULTS: A total of 170 women received a histological diagnosis of AC and 42 of ASC. The median follow-up was 56.7 months. There were no significant differences in age, International Federation of Gynecology and Obstetrics (FIGO) stage, gravidity or treatment modality between women with AC and ASC. Patients with ASC had a higher percentage of poorly differentiated tumors than those with AC (33.3 vs. 15.3%, respectively; p= 0.014). Five year overall and recurrence-free survival was 66.8 and 58.9%, respectively, for women with AC and 69.5 and 61.9%, respectively, for those with ASC (p= 0.795 and p= 0.892, respectively). Survival outcomes in patients with early or advanced stage disease did not differ between the histological groups. No differences in failure patterns were found between the two groups. The FIGO stage and treatment modality were factors which affected overall and recurrence-free survival. CONCLUSIONS: We did not find evidence to suggest that ASC subtypes indicate worse outcome. Cervical ASC could be categorized as one subtype of AC. The FIGO stage and treatment modalities have greater influence on outcomes than histological subtype.
    [Abstract] [Full Text] [Related] [New Search]